Open-house rebate agreement for Sarilumab
Originaltitel der Bekanntmachung
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sarilumab, ATC L04AC14
Opportunity Score
Warum diese Bewertung?
Chance
62 / 100
Komplexität
48 / 100
Risikofaktoren
The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...
The notice references procurement documents and an annex, but only the notice text was provided; the full document set...
Submission deadline in 8 days
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Überblick
Moderate opportunityWichtige Fakten
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive open-house rebate agreements for the medicinal product substance Sarilumab, ATC L04AC14.
- Supply contract for pharmaceutical products.
Vollständige Zusammenfassung anzeigen
This is an open-house pharmaceutical supply arrangement for Sarilumab (ATC L04AC14) led by AOK Bayern. It is not a competitive award procedure in the usual sense: the notice states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 2024-11-01 to 2026-10-31, with contract entry possible until 2026-09-05. Submission is allowed electronically with a qualified electronic signature or in paper form, and the notice requires German-language submission or German translation for non-German documents. No contract value is stated.
Risiken
The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...
The notice references procurement documents and an annex, but only the notice text was provided; the full document set...
Submission deadline in 8 days
Analyse kann unvollständig sein
Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.
Wichtige Anforderungen
Technical
- The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
Auftraggeber
Ort
München, DEU
Website
Auftraggeberprofil
Kennung
DE811695320
Tätigkeit
Health
Lose (1)
LOT-0001
Open-house rebate agreement for Sarilumab
Single lot for non-exclusive open-house rebate agreements concerning the pharmaceutical substance Sarilumab (ATC L04AC14). The lot is for supplies and is performance-related to Germany, specifically Bavaria (DE212).
Ort
Dauer
Kategorie
Frist
Zuschlagsdetails
Siehe kurze Beschreibung
Hinweis zum Wert
Originale TED-Daten anzeigen
Originaler Los-Titel
Open house Arzneimittelrabattverträge Sarilumab, ATC L04AC14
Originale TED-Beschreibung
Siehe kurze Beschreibung
Vergabedetails
- Veröffentlichungsdatum
- 16 Sep 2024
- Sprachen
- German
Referenzmetadaten
- Rechtsgrundlage
- 32014L0024
Referenz-IDs
- Ausschreibungs-ID
- 557248-2024
Dokumente (2)
Ähnliche Ausschreibungen
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Warum diese Bewertung?
Chance
62 / 100
Komplexität
48 / 100
Risikofaktoren
The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...
The notice references procurement documents and an annex, but only the notice text was provided; the full document set...
Submission deadline in 8 days
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications